GlassScriptPhysician profile
Maureen Ann Duke
NPI 1760577530
$7,161.11
in general payments reported to CMS, 2019-2025
28 companies · $2,362 in 2025
The $2,362 reported for 2025 was more than what 93% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $137 · 2022: $483 · 2023: $2,079 · 2024: $2,100 · 2025: $2,362.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,467 · Consulting Fee: $50.98 · Education: $22.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,467.16 |
| Consulting Fee | $50.98 |
| Education | $22.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,390.14 | 2021-2025 | Airsupra, Fasenra, Breztri |
| Glaxosmithkline, LLC. | $1,322.21 | 2021-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Regeneron Healthcare Solutions, INC. | $862.46 | 2022-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $543.63 | 2023-2025 | Cuvitru, Hyqvia, Takhzyro |
| Genzyme Corporation | $511.13 | 2022-2025 | |
| Biocryst US Sales Co., LLC | $404.78 | 2022-2025 | Orladeyo |
| Grifols USA, LLC | $329.33 | 2023-2025 | Xembify, Prolastin-C Liquid |
| Genentech USA, INC. | $317.04 | 2023-2025 | Xolair |
| Csl Behring | $274.75 | 2022-2025 | Haegarda, Andembry, Kcentra |
| Amgen INC. | $215.59 | 2022-2025 | Tezspire |
| Pfizer INC. | $204.73 | 2022-2025 | |
| Leo Pharma INC. | $109.15 | 2022-2023 | Adbry |
| Optinose US, INC. | $83.53 | 2023-2024 | |
| Novartis Pharmaceuticals Corporation | $82.54 | 2025 | |
| Blueprint Medicines Corporation | $76.66 | 2023 | Ayvakit, Gavreto |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharming Healthcare, INC. | $52.76 | 2025 | Ruconest |
| Merck Sharp & Dohme LLC | $51.42 | 2023 | |
| Adma Biomanufacturing LLC | $50.98 | 2024-2025 | |
| Ars Pharmaceuticals Operations, INC. | $44.97 | 2025 | Neffy |
| Kaleo, INC. | $44.37 | 2023 | Auvi-Q |
| Incyte Corporation | $38.16 | 2024-2025 | Opzelura |
| Phadia US INC. | $35.39 | 2024 | Immunocap |
| Kedrion Biopharma, INC. | $28.74 | 2024 | Gammaked, Kedrab, Koate |
| Verona Pharma, INC. | $19.11 | 2025 | Ohtuvayre |
| Invivyd INC | $18.25 | 2024 | Pemgarda |
| Paratek Pharmaceuticals, INC. | $17.62 | 2025 | Xhance |
| Octapharma USA, INC. | $15.92 | 2023 | Cutaquig |
| Azurity Pharmaceuticals, INC. | $15.75 | 2025 | Alvesco |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maureen Duke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.